Why the study?
Does intravenous exenatide improve myocardial salvage in patients with STEMI undergoing percutaneous coronary intervention, and is this effect dependent on admission hyperglycemia?
Population
210 patients with ST-segment elevation myocardial infarction (STEMI)
Comparison
Intravenous exenatide before percutaneous… vs Placebo before percutaneous coronary intervention
Design
RCT, randomized
Authors
Loading...
Supports exenatide for myocardial salvage in STEMI independent of glycemia; extends cardioprotection evidence across glucose strata.
Does intravenous exenatide improve myocardial salvage in patients with STEMI undergoing percutaneous coronary intervention, and is this effect dependent on admission hyperglycemia?
Cardioprotection by exenatide treatment in STEMI patients is independent of glucose levels at hospital admission, and hyperglycemia acts as a surrogate marker for the severity of risk and injury rather than directly reducing myocardial salvage.
Lønborg et al. (2014) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: